REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025
Alvotech Investor Relations
Benedikt Stefansson
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.50 |
| Daily Change: | 0.53 6.65 |
| Daily Volume: | 620,109 |
| Market Cap: | US$2.650B |
October 06, 2025 September 22, 2025 September 22, 2025 September 19, 2025 August 21, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
